APOE and Alzheimer’s disease: Advances in genetics, pathophysiology, and therapeutic approaches
Open accessAbstract
The APOE ε4 allele remains the strongest genetic risk factor for sporadic Alzheimer's disease and the APOE ε2 allele the strongest genetic protective factor after multiple large scale genome-wide association studies and genome-wide association meta-analyses. However, no therapies directed at APOE are currently available. Although initial studies causally linked APOE with amyloid-β peptide aggregation and clearance, over the past 5 years our understanding of APOE pathogenesis has expanded beyond amyloid-β peptide-centric mechanisms to tau neurofibrillary degeneration, microglia and astrocyte responses, and blood-brain barrier disruption. Because all these pathological processes can potentially contribute to cognitive impairment, it is important to use this new knowledge to develop therapies directed at APOE. Several therapeutic approaches have been successful in mouse models expressing human APOE alleles, including increasing or reducing APOE levels, enhancing its lipidation, blocking the interactions between APOE and amyloid-β peptide, and genetically switching APOE4 to APOE3 or APOE2 isoforms, but translation to human clinical trials has proven challenging.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Individuals carrying the APOE ε4 allele display distinct proteo-metabolomic signatures in lipid transport and immune pathways.
“For example, individuals carrying the APOE ε4 allele display distinct proteo-metabolomic signatures in lipid transport and immune pathways206,207.”
From Artificial intelligence-driven multi-omics approaches in Alzheimer's disease: Progress, challenges, and future directions (2025) · cites this paper as [206]
Panel 1 reports APOE4-specific differences in lipid binding and transport, and “Effects on glia” reports proinflammatory changes in APOE4 microglia. However, the paper does not report distinct proteo-metabolomic signatures in individuals carrying ε4; its immune-pathway evidence here concerns gene expression in mouse and stem-cell-derived microglia. (LLM, conf=0.84)
Experimental — accuracy not yet measuredAPOE genotype remains the strongest known risk factor for late-onset Alzheimer's disease.
“However, apolipoprotein E (APOE) genotype remains the strongest known risk factor. 1”
From Deletion of neuronal <i>Idol</i> ameliorates Alzheimer's disease–related pathologies via APOE receptors (2025) · cites this paper as [1]
The Introduction calls the APOE ε4 allele the strongest genetic risk factor for sporadic Alzheimer’s disease. The citing sentence omits “genetic,” so the source does not support calling APOE genotype the strongest known risk factor overall. No page number is available in our copy. (LLM, conf=0.88)
Experimental — accuracy not yet measuredCarrying one copy of the APOE ε4 allele increases the risk of developing Alzheimer's disease by about 3 to 7 times.
“Carrying one copy of this allele increases the risk of developing AD by about 3 to 7 times”
From Apoe4 and Alzheimer’s Disease Pathogenesis—Mitochondrial Deregulation and Targeted Therapeutic Strategies (2023) · cites this paper as [17]
Panel 1 (Apolipoprotein E basic facts; page not specified) says that, relative to APOE ε3/ε3, possessing one ε4 allele increases Alzheimer’s disease risk by approximately 3.7 times. That supports an increase of roughly three to four times, but the passage does not give a range extending to seven times for one copy. (LLM, conf=0.85)
Experimental — accuracy not yet measuredApoE4 promotes APP-mediated activation of microglia.
“ApoE4 potentiates inflammatory cascades, modifies microglial phenotype towards a proinflammatory profile and promotes APP-mediated activation of microglia [17]”
From Apoe4 and Alzheimer’s Disease Pathogenesis—Mitochondrial Deregulation and Targeted Therapeutic Strategies (2023) · cites this paper as [17]
The ‘Effects on glia’ section reports that APOE4 microglia are primed toward a proinflammatory phenotype and that APOE and TREM2 influence microglial responses to Aβ plaques. It does not establish that APOE4 promotes APP-mediated activation of microglia; it also reports no difference between APOE ε4 carriers and non-carriers in activated microglia per Aβ plaque in the post-mortem sections studied. Page numbers are unavailable in our copy. (LLM, conf=0.86)
Experimental — accuracy not yet measuredApoE3 and ApoE2 proteins are less susceptible to proteolytical cleavage than ApoE4 due to their structural properties.
“To genetically convert ApoE4 into ApoE3 or ApoE2 proteins would be also hypothetically effective in reducing ApoE fragments since their structural properties make these proteins less susceptible to proteolytical cleavage; this would also protect against AD-related phenotypical alterations that have been extensively attributed to ApoE4 [17].”
From Apoe4 and Alzheimer’s Disease Pathogenesis—Mitochondrial Deregulation and Targeted Therapeutic Strategies (2023) · cites this paper as [17]
In “Effects on Aβ” (page not provided), the paper says APOE4’s conformation could increase its propensity for enzymatic cleavage relative to APOE3 and APOE2, producing more C-terminal fragments. The citing sentence presents that proposed structural mechanism as an established cause of lower cleavage susceptibility in APOE3 and APOE2. (LLM, conf=0.85)
Experimental — accuracy not yet measured
Previous human and animal studies have established the baseline consequences of APOE3 and APOE4 in the absence of amyloid pathology.
“Previous human and animal studies have already established the baseline consequences of APOE3 and APOE4 in the absence of amyloid pathology. 60 , 61 , 62 , 63”
From Apolipoprotein ε4 exacerbates white matter impairment in a mouse model of Aβ amyloidosis by decreasing actively myelinating oligodendrocytes (2025) · cites this paper as [61]
APOE ε2 is the most protective common inherited variant for AD.
“which is the most protective common inherited variant for AD26.”
From Clonal hematopoiesis is associated with protection from Alzheimer’s disease (2023) · cites this paper as [26]
CHIP may exert its strongest influence in individuals lacking the dominant amyloid-promoting or amyloid-protective effects conferred by APOE ε4 or APOE ε2, respectively.
“This interaction suggests that CHIP may exert its strongest influence in individuals lacking the dominant amyloid-promoting or amyloid-protective effects conferred by APOE ε4 or APOE ε2, respectively [41].”
From Clonal Hematopoiesis of Indeterminate Potential as an Emerging Interdisciplinary Risk Factor in Alzheimer’s Disease: Current Evidence and Future Directions (2026) · cites this paper as [41]
Functional diversity of APOE isoforms profoundly impacts astrocyte biology.
“The functional diversity of APOE isoforms profoundly impacts astrocyte biology.”
From Protective mechanisms against Alzheimer's disease in APOE3‐Christchurch homozygous astrocytes (2025) · cites this paper as [5]
APOE4 is the major genetic risk factor for sporadic Alzheimer's disease.
“APOE4, the major genetic risk factor for sporadic AD (Serrano-Pozo et al., 2021)”
From APOE4 reduces hippocampal expression of phosphoglycerate kinase 1 and sodium potassium pump to enhance seizure susceptibility in mice (2026) · cites this paper as Serrano-Pozo et al., 2021
ApoE4 directly interacts with both soluble and fibrillar forms of Aβ, accelerating its oligomerization and deposition in the brain.
“ApoE4 is able to directly interact with both soluble and fibrillar forms of Aβ [17,38], accelerating its oligomerization and deposition in the brain [2].”
From Apoe4 and Alzheimer’s Disease Pathogenesis—Mitochondrial Deregulation and Targeted Therapeutic Strategies (2023) · cites this paper as [17]
Carrying one copy of the APOE ε2 allele reduces the risk of developing Alzheimer's disease by about 40%.
“carrying one copy of the APOE ε2 allele (ApoE2) reduces the risk of developing AD by about 40% [17]”
From Apoe4 and Alzheimer’s Disease Pathogenesis—Mitochondrial Deregulation and Targeted Therapeutic Strategies (2023) · cites this paper as [17]
Carrying two copies of the APOE ε4 allele increases the risk of developing Alzheimer's disease up to 12 times.
“while carrying two copies increases the risk up to 12 times [17]”
From Apoe4 and Alzheimer’s Disease Pathogenesis—Mitochondrial Deregulation and Targeted Therapeutic Strategies (2023) · cites this paper as [17]
Astrocytes expressing ApoE4 are linked to reduced neurotrophic support.
“astrocytes expressing ApoE4 have been linked to reduced neurotrophic support [17].”
From Apoe4 and Alzheimer’s Disease Pathogenesis—Mitochondrial Deregulation and Targeted Therapeutic Strategies (2023) · cites this paper as [17]
ApoE4 potentiates inflammatory cascades.
“ApoE4 potentiates inflammatory cascades, modifies microglial phenotype towards a proinflammatory profile and promotes APP-mediated activation of microglia [17]”
From Apoe4 and Alzheimer’s Disease Pathogenesis—Mitochondrial Deregulation and Targeted Therapeutic Strategies (2023) · cites this paper as [17]
ApoE4 modifies microglial phenotype towards a proinflammatory profile.
“ApoE4 potentiates inflammatory cascades, modifies microglial phenotype towards a proinflammatory profile and promotes APP-mediated activation of microglia [17]”
From Apoe4 and Alzheimer’s Disease Pathogenesis—Mitochondrial Deregulation and Targeted Therapeutic Strategies (2023) · cites this paper as [17]
Apolipoprotein E plays a key role in microglia-dependent and astrocyte-dependent regulation of tau pathology and tau-induced neurodegeneration.
“Apolipoprotein E (ApoE) also plays a key role in the microglia-dependent and astrocyte-dependent regulation of tau pathology and tau-induced neurodegeneration [41,42].”
From Role of Tau Protein in Neurodegenerative Diseases and Development of Its Targeted Drugs: A Literature Review (2024) · cites this paper as [41]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
1 retracted
RETRACTED ARTICLE: Pericyte loss influences Alzheimer-like neurodegeneration in mice
Sagare, A. P., Bell, R. D., Zhao, Z., Ma, Q., Winkler, E. A., Ramanathan, A., & Zlokovic, B. V. (2013) · Nature Communications · doi:10.1038/ncomms3932 · Cited by 589 · see citing works
RetractedA Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493 · see citing works
Krasemann, S., Madore, C., Cialic, R., Baufeld, C., Calcagno, N., El Fatimy, R., Beckers, L., O’Loughlin, E., Xu, Y., Fanek, Z., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.08.008 · Cited by 2,979 · see citing works
Alzheimer Disease Genetics Consortium (ADGC), Kunkle, B. W., The European Alzheimer’s Disease Initiative (EADI), Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (CHARGE), Genetic and Environmental Risk in AD/Defining Genetic, P. A. E. R. F. A. D. C. (., Grenier-Boley, B., Sims, R., Bis, J. C., Damotte, V., Naj, A. C., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0358-2 · Cited by 2,946 · see citing works
Self-citationSingle-cell transcriptomic analysis of Alzheimer’s disease
Mathys, H., Davila-Velderrain, J., Peng, Z., Gao, F., Mohammadi, S., Young, J. Z., Menon, M., He, L., Abdurrob, F., Jiang, X., et al. (2019) · Nature · doi:10.1038/s41586-019-1195-2 · Cited by 2,568 · see citing works
Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis
Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Aalten, P., Aarsland, D., Alcolea, D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4668 · Cited by 1,610 · see citing works
Apolipoprotein E controls cerebrovascular integrity via cyclophilin A
Bell, R. D., Winkler, E. A., Singh, I., Sagare, A. P., Deane, R., Wu, Z., Holtzman, D. M., Betsholtz, C., Armulik, A., Sallstrom, J., et al. (2012) · Nature · doi:10.1038/nature11087 · Cited by 1,293 · see citing works
APOE4 leads to blood–brain barrier dysfunction predicting cognitive decline
Montagne, A., Nation, D. A., Sagare, A. P., Barisano, G., Sweeney, M. D., Chakhoyan, A., Pachicano, M., Joe, E., Nelson, A. R., D’Orazio, L. M., et al. (2020) · Nature · doi:10.1038/s41586-020-2247-3 · Cited by 1,281 · see citing works
Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,227 · see citing works
ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy
Initiative, A. D. N., Shi, Y., Yamada, K., Liddelow, S. A., Smith, S. T., Zhao, L., Luo, W., Tsai, R. M., Spina, S., Grinberg, L. T., et al. (2017) · Nature · doi:10.1038/nature24016 · Cited by 1,220 · see citing works
Zhou, Y., Song, W. M., Andhey, P. S., Swain, A., Levy, T., Miller, K. R., Poliani, P. L., Cominelli, M., Grover, S., Gilfillan, S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-019-0695-9 · Cited by 1,150 · see citing works
Lin, Y.-T., Seo, J., Gao, F., Feldman, H. M., Wen, H.-L., Penney, J., Cam, H. P., Gjoneska, E., Raja, W. K., Cheng, J., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.05.008 · Cited by 1,125 · see citing works
Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions
William Rebeck, G., Reiter, J. S., Strickland, D. K., & Hyman, B. T. (1993) · Neuron · doi:10.1016/0896-6273(93)90070-8 · Cited by 1,107 · see citing works
Self-citationApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models
Cramer, P. E., Cirrito, J. R., Wesson, D. W., Lee, C. Y. D., Karlo, J. C., Zinn, A. E., Casali, B. T., Restivo, J. L., Goebel, W. D., James, M. J., et al. (2012) · Science · doi:10.1126/science.1217697 · Cited by 1,050 · see citing works
Grubman, A., Chew, G., Ouyang, J. F., Sun, G., Choo, X. Y., McLean, C., Simmons, R. K., Buckberry, S., Vargas-Landin, D. B., Poppe, D., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0539-4 · Cited by 956 · see citing works
Holtzman, D. M., Bales, K. R., Tenkova, T., Fagan, A. M., Parsadanian, M., Sartorius, L. J., Mackey, B., Olney, J., McKeel, D., Wozniak, D., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050004797 · Cited by 937 · see citing works
Tang, M.-X. (1998) · JAMA · doi:10.1001/jama.279.10.751 · Cited by 771 · see citing works
apoE isoform–specific disruption of amyloid β peptide clearance from mouse brain
Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M. B., Holtzman, D. M., & Zlokovic, B. V. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36663 · Cited by 771 · see citing works
Robinson, J. L., Lee, E. B., Xie, S. X., Rennert, L., Suh, E., Bredenberg, C., Caswell, C., Van Deerlin, V. M., Yan, N., Yousef, A., et al. (2018) · Brain · doi:10.1093/brain/awy146 · Cited by 729 · see citing works
Amyloid β oligomers constrict human capillaries in Alzheimer's disease via signaling to pericytes
Nortley, R., Korte, N., Izquierdo, P., Hirunpattarasilp, C., Mishra, A., Jaunmuktane, Z., Kyrargyri, V., Pfeiffer, T., Khennouf, L., Madry, C., et al. (2019) · Science · doi:10.1126/science.aav9518 · Cited by 682 · see citing works
Prevalence of Amyloid PET Positivity in Dementia Syndromes: A Meta-analysis
Ossenkoppele, R., Jansen, W. J., Rabinovici, G. D., Knol, D. L., van der Flier, W. M., van Berckel, B. N. M., Scheltens, P., Visser, P. J., Verfaillie, S. C. J., Zwan, M. D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4669 · Cited by 677 · see citing works
Arboleda-Velasquez, J. F., Lopera, F., O’Hare, M., Delgado-Tirado, S., Marino, C., Chmielewska, N., Saez-Torres, K. L., Amarnani, D., Schultz, A. P., Sperling, R. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0611-3 · Cited by 598 · see citing works
Apolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2)
Atagi, Y., Liu, C.-C., Painter, M. M., Chen, X.-F., Verbeeck, C., Zheng, H., Li, X., Rademakers, R., Kang, S. S., Xu, H., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.679043 · Cited by 587 · see citing works
Verghese, P. B., Castellano, J. M., Garai, K., Wang, Y., Jiang, H., Shah, A., Bu, G., Frieden, C., & Holtzman, D. M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220484110 · Cited by 556 · see citing works
Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE
Parhizkar, S., Arzberger, T., Brendel, M., Kleinberger, G., Deussing, M., Focke, C., Nuscher, B., Xiong, M., Ghasemigharagoz, A., Katzmarski, N., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-018-0296-9 · Cited by 555 · see citing works
LRP1 is a master regulator of tau uptake and spread
Rauch, J. N., Luna, G., Guzman, E., Audouard, M., Challis, C., Sibih, Y. E., Leshuk, C., Hernandez, I., Wegmann, S., Hyman, B. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2156-5 · Cited by 541 · see citing works
Self-citationSperling, R., Salloway, S., Brooks, D. J., Tampieri, D., Barakos, J., Fox, N. C., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70015-7 · Cited by 512 · see citing works
Reiman, E. M., Arboleda-Velasquez, J. F., Quiroz, Y. T., Huentelman, M. J., Beach, T. G., Caselli, R. J., Chen, Y., Su, Y., Myers, A. J., Hardy, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14279-8 · Cited by 473 · see citing works
Self-citationApoE4 Accelerates Early Seeding of Amyloid Pathology
Liu, C.-C., Zhao, N., Fu, Y., Wang, N., Linares, C., Tsai, C.-W., & Bu, G. (2017) · Neuron · doi:10.1016/j.neuron.2017.11.013 · Cited by 451 · see citing works
Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model
Shi, Y., Manis, M., Long, J., Wang, K., Sullivan, P. M., Remolina Serrano, J., Hoyle, R., & Holtzman, D. M. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20190980 · Cited by 448 · see citing works
APOE ϵ4 Increases Risk for Dementia in Pure Synucleinopathies
Tsuang, D., Leverenz, J. B., Lopez, O. L., Hamilton, R. L., Bennett, D. A., Schneider, J. A., Buchman, A. S., Larson, E. B., Crane, P. K., Kaye, J. A., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.600 · Cited by 378 · see citing works
Evans, D. A., Bennett, D. A., Wilson, R. S., Bienias, J. L., Morris, M. C., Scherr, P. A., Hebert, L. E., Aggarwal, N., Beckett, L. A., Joglekar, R., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.2.185 · Cited by 370 · see citing works
Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease
Wahrle, S. E., Jiang, H., Parsadanian, M., Kim, J., Li, A., Knoten, A., Jain, S., Hirsch-Reinshagen, V., Wellington, C. L., Bales, K. R., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33622 · Cited by 370 · see citing works
Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation.
Linton, M. F., Gish, R., Hubl, S. T., Bütler, E., Esquivel, C., Bry, W. I., Boyles, J. K., Wardell, M. R., & Young, S. G. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115288 · Cited by 367 · see citing works
Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE
Parhizkar, S., Arzberger, T., Brendel, M., Kleinberger, G., Deußing, M., Focke, C., Nuscher, B., Xiong, M., Ghasemigharagoz, A., Katzmarski, N., et al. (2019) · doi:10.7892/boris.125653 · Cited by 352 · see citing works
Apolipoprotein E4 effects in Alzheimer’s disease are mediated by synaptotoxic oligomeric amyloid-β
Koffie, R. M., Hashimoto, T., Tai, H.-C., Kay, K. R., Serrano-Pozo, A., Joyner, D., Hou, S., Kopeikina, K. J., Frosch, M. P., Lee, V. M., et al. (2012) · Brain · doi:10.1093/brain/aws127 · Cited by 327 · see citing works
Self-citationDeletion of Abca1 Increases Aβ Deposition in the PDAPP Transgenic Mouse Model of Alzheimer Disease
Wahrle, S. E., Jiang, H., Parsadanian, M., Hartman, R. E., Bales, K. R., Paul, S. M., & Holtzman, D. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508780200 · Cited by 325 · see citing works
ApoE facilitates the microglial response to amyloid plaque pathology
Ulrich, J. D., Ulland, T. K., Mahan, T. E., Nyström, S., Nilsson, K. P., Song, W. M., Zhou, Y., Reinartz, M., Choi, S., Jiang, H., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171265 · Cited by 297 · see citing works
Apolipoprotein E, Especially Apolipoprotein E4, Increases the Oligomerization of Amyloid β Peptide
Hashimoto, T., Serrano-Pozo, A., Hori, Y., Adams, K. W., Takeda, S., Banerji, A. O., Mitani, A., Joyner, D., Thyssen, D. H., Bacskai, B. J., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1542-12.2012 · Cited by 294 · see citing works
Self-citationBlanchard, J. W., Bula, M., Davila-Velderrain, J., Akay, L. A., Zhu, L., Frank, A., Victor, M. B., Bonner, J. M., Mathys, H., Lin, Y.-T., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0886-4 · Cited by 283 · see citing works
Ma, Q., Zhao, Z., Sagare, A. P., Wu, Y., Wang, M., Owens, N. C., Verghese, P. B., Herz, J., Holtzman, D. M., & Zlokovic, B. V. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0286-0 · Cited by 281 · see citing works
Neuronal Clearance of Amyloid-β by Endocytic Receptor LRP1
Kanekiyo, T., Cirrito, J. R., Liu, C.-C., Shinohara, M., Li, J., Schuler, D. R., Shinohara, M., Holtzman, D. M., & Bu, G. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.3487-13.2013 · Cited by 280 · see citing works
Kim, J., Castellano, J. M., Jiang, H., Basak, J. M., Parsadanian, M., Pham, V., Mason, S. M., Paul, S. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.11.013 · Cited by 274 · see citing works
Astrocytic LRP1 Mediates Brain Aβ Clearance and Impacts Amyloid Deposition
Liu, C.-C., Hu, J., Zhao, N., Wang, J., Wang, N., Cirrito, J. R., Kanekiyo, T., Holtzman, D. M., & Bu, G. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.3442-16.2017 · Cited by 267 · see citing works
APOE4-specific Changes in Aβ Accumulation in a New Transgenic Mouse Model of Alzheimer Disease
Youmans, K. L., Tai, L. M., Nwabuisi-Heath, E., Jungbauer, L., Kanekiyo, T., Gan, M., Kim, J., Eimer, W. A., Estus, S., Rebeck, G. W., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.407957 · Cited by 259 · see citing works
Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β
Therriault, J., Benedet, A. L., Pascoal, T. A., Mathotaarachchi, S., Chamoun, M., Savard, M., Thomas, E., Kang, M. S., Lussier, F., Tissot, C., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2019.4421 · Cited by 256 · see citing works
Novel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes
Chung, W.-S., Verghese, P. B., Chakraborty, C., Joung, J., Hyman, B. T., Ulrich, J. D., Holtzman, D. M., & Barres, B. A. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1609896113 · Cited by 242 · see citing works
Self-citationPotentially modifiable risk factors for dementia in identical twins
Gatz, M., Mortimer, J. A., Fratiglioni, L., Johansson, B., Berg, S., Reynolds, C. A., & Pedersen, N. L. (2006) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2006.01.002 · Cited by 239 · see citing works
Alzheimer’s Risk Factors Age, APOE Genotype, and Sex Drive Distinct Molecular Pathways
Zhao, N., Ren, Y., Yamazaki, Y., Qiao, W., Li, F., Felton, L. M., Mahmoudiandehkordi, S., Kueider-Paisley, A., Sonoustoun, B., Arnold, M., et al. (2020) · Neuron · doi:10.1016/j.neuron.2020.02.034 · Cited by 225 · see citing works
LRP1 in Brain Vascular Smooth Muscle Cells Mediates Local Clearance of Alzheimer's Amyloid-β
Kanekiyo, T., Liu, C., Shinohara, M., Li, J., & Bu, G. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.3987-12.2012 · Cited by 221 · see citing works
APOE ε4/ε4 diminishes neurotrophic function of human iPSC-derived astrocytes
Zhao, J., Davis, M. D., Martens, Y. A., Shinohara, M., Graff-Radford, N. R., Younkin, S. G., Wszolek, Z. K., Kanekiyo, T., & Bu, G. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx155 · Cited by 221 · see citing works
<i>APOE</i> ε4 is associated with severity of Lewy body pathology independent of Alzheimer pathology
Dickson, D. W., Heckman, M. G., Murray, M. E., Soto, A. I., Walton, R. L., Diehl, N. N., van Gerpen, J. A., Uitti, R. J., Wszolek, Z. K., Ertekin-Taner, N., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000006212 · Cited by 210 · see citing works
Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of β-amyloidosis
Huynh, T.-P. V., Liao, F., Francis, C. M., Robinson, G. O., Serrano, J. R., Jiang, H., Roh, J., Finn, M. B., Sullivan, P. M., Esparza, T. J., et al. (2017) · Neuron · doi:10.1016/j.neuron.2017.11.014 · Cited by 209 · see citing works
Ancestral origin of ApoE ε4 Alzheimer disease risk in Puerto Rican and African American populations
Rajabli, F., Feliciano, B. E., Celis, K., Hamilton-Nelson, K. L., Whitehead, P. L., Adams, L. D., Bussies, P. L., Manrique, C. P., Rodriguez, A., Rodriguez, V., et al. (2018) · PLOS Genetics · doi:10.1371/journal.pgen.1007791 · Cited by 206 · see citing works
Kim, J., Jiang, H., Park, S., Eltorai, A. E. M., Stewart, F. R., Yoon, H., Basak, J. M., Finn, M. B., & Holtzman, D. M. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3773-11.2011 · Cited by 199 · see citing works
Cummings, J. L., Zhong, K., Kinney, J. W., Heaney, C., Moll-Tudla, J., Joshi, A., Pontecorvo, M., Devous, M., Tang, A., & Bena, J. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0173-2 · Cited by 190 · see citing works
Hudry, E., Dashkoff, J., Roe, A. D., Takeda, S., Koffie, R. M., Hashimoto, T., Scheel, M., Spires-Jones, T., Arbel-Ornath, M., Betensky, R., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007000 · Cited by 187 · see citing works
Self-citationTargeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation
Liao, F., Li, A., Xiong, M., Bien-Ly, N., Jiang, H., Zhang, Y., Finn, M. B., Hoyle, R., Keyser, J., Lefton, K. B., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96429 · Cited by 178 · see citing works
Self-citationSerrano‐Pozo, A., Qian, J., Monsell, S. E., Betensky, R. A., & Hyman, B. T. (2015) · Annals of Neurology · doi:10.1002/ana.24369 · Cited by 176 · see citing works
Self-citationHu, J., Liu, C.-C., Chen, X.-F., Zhang, Y.-W., Xu, H., & Bu, G. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0001-3 · Cited by 161 · see citing works
Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβ amyloidosis
Kim, J., Eltorai, A. E. M., Jiang, H., Liao, F., Verghese, P. B., Kim, J., Stewart, F. R., Basak, J. M., & Holtzman, D. M. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20121274 · Cited by 160 · see citing works
Han, S., Hulette, C., Saunders, A. M., Einstein, G., Pericak‐Vance, M. A., Strittmatter, W. J., Roses, A. D., & Schmechel, D. E. (1994) · Experimental Neurology · doi:10.1006/exnr.1994.1108 · Cited by 155 · see citing works
Castellano, J. M., Deane, R., Gottesdiener, A. J., Verghese, P. B., Stewart, F. R., West, T., Paoletti, A. C., Kasper, T. R., DeMattos, R. B., Zlokovic, B. V., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206446109 · Cited by 154 · see citing works
Fitz, N. F., Cronican, A. A., Lefterov, I., & Koldamova, R. (2013) · Science · doi:10.1126/science.1235809 · Cited by 151 · see citing works
Yang, H., Yu, L., White, C. C., Chibnik, L. B., Chhatwal, J. P., Sperling, R. A., Bennett, D., Schneider, J. A., & Jager, P. L. D. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30251-5 · Cited by 145 · see citing works
APOE ε2 is associated with increased tau pathology in primary tauopathy
Zhao, N., Liu, C.-C., Van Ingelgom, A. J., Linares, C., Kurti, A., Knight, J. A., Heckman, M. G., Diehl, N. N., Shinohara, M., Martens, Y. A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06783-0 · Cited by 139 · see citing works
Huynh, T.-P. V., Wang, C., Tran, A. C., Tabor, G. T., Mahan, T. E., Francis, C. M., Finn, M. B., Spellman, R., Manis, M., Tanzi, R. E., et al. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0337-1 · Cited by 139 · see citing works
Price, A. R., Xu, G., Siemienski, Z. B., Smithson, L. A., Borchelt, D. R., Golde, T. E., & Felsenstein, K. M. (2013) · Science · doi:10.1126/science.1234089 · Cited by 138 · see citing works
Veeraraghavalu, K., Zhang, C., Miller, S., Hefendehl, J. K., Rajapaksha, T. W., Ulrich, J., Jucker, M., Holtzman, D. M., Tanzi, R. E., Vassar, R., et al. (2013) · Science · doi:10.1126/science.1235505 · Cited by 133 · see citing works
ApoE immunoreactivity and microglial cells in Alzheimer’s disease brain
Uchihara, T., Duyckaerts, C., He, Y., Kobayashi, K., Seilhean, D., Amouyel, P., & Hauw, J.-J. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11763-m · Cited by 131 · see citing works
Liao, F., Hori, Y., Hudry, E., Bauer, A. Q., Jiang, H., Mahan, T. E., Lefton, K. B., Zhang, T. J., Dearborn, J. T., Kim, J., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.0646-14.2014 · Cited by 128 · see citing works
Self-citationTesseur, I., Lo, A. C., Roberfroid, A., Dietvorst, S., Van Broeck, B., Borgers, M., Gijsen, H., Moechars, D., Mercken, M., Kemp, J., et al. (2013) · Science · doi:10.1126/science.1233937 · Cited by 128 · see citing works
Farrer, L. A. (1997) · JAMA · doi:10.1001/jama.1997.03550160069041 · Cited by 124 · see citing works
Non-coding variability at the APOE locus contributes to the Alzheimer’s risk
Zhou, X., Chen, Y., Mok, K. Y., Kwok, T. C. Y., Mok, V. C. T., Guo, Q., Ip, F. C., Chen, Y., Mullapudi, N., Initiative, A. D. N., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10945-z · Cited by 120 · see citing works
ABCA1 Agonist Reverses the ApoE4-Driven Cognitive and Brain Pathologies
Boehm-Cagan, A., Bar, R., Liraz, O., Bielicki, J. K., Johansson, J. O., & Michaelson, D. M. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160467 · Cited by 116 · see citing works
Local ancestry at APOE modifies Alzheimer's disease risk in Caribbean Hispanics
Blue, E., Horimoto, A. R. V. R., Mukherjee, S., Wijsman, E. M., & Thornton, T. A. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.07.016 · Cited by 110 · see citing works
Belloy, M. E., Napolioni, V., Han, S. S., Le Guen, Y., Greicius, M. D., & Initiative, F. T. A. D. N. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.0414 · Cited by 110 · see citing works
Plaque-associated local toxicity increases over the clinical course of Alzheimer disease
Serrano-Pozo, A., Betensky, R. A., Frosch, M. P., & Hyman, B. T. (2016) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.10.010 · Cited by 100 · see citing works
Self-citationApolipoprotein E and lipid homeostasis in the etiology and treatment of sporadic Alzheimer's disease
Poirier, J., Miron, J., Picard, C., Gormley, P., Théroux, L., Breitner, J. C. S., & Dea, D. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.03.037 · Cited by 98 · see citing works
Reversal of ApoE4-induced recycling block as a novel prevention approach for Alzheimer’s disease
Xian, X., Pohlkamp, T., Durakoglugil, M. S., Wong, C. H., Beck, J. K., Lane-Donovan, C., Plattner, F., & Herz, J. (2018) · eLife · doi:10.7554/elife.40048 · Cited by 98 · see citing works
Mak, A. C. Y., Pullinger, C. R., Tang, L. F., Wong, J. S., Deo, R. C., Schwarz, J.-M., Gugliucci, A., Movsesyan, I., Ishida, B. Y., Chu, C., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.2011 · Cited by 96 · see citing works
Association of Apolipoprotein E ε4 With Transactive Response DNA-Binding Protein 43
Wennberg, A. M. V., Tosakulwong, N., Lesnick, T. G., Murray, M. E., Whitwell, J. L., Liesinger, A. M., Petrucelli, L., Boeve, B. F., Parisi, J. E., Knopman, D. S., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.3139 · Cited by 96 · see citing works
Amyloid-β Pathology and APOE Genotype Modulate Retinoid X Receptor Agonist Activity in Vivo
Tai, L. M., Koster, K. P., Luo, J., Lee, S., Wang, Y., Collins, N. C., Aissa, M. B., Thatcher, G. R. J., & LaDu, M. J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.600833 · Cited by 93 · see citing works
Yamazaki, Y., Shinohara, M., Yamazaki, A., Ren, Y., Asmann, Y. W., Kanekiyo, T., & Bu, G. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.313169 · Cited by 89 · see citing works
Santos, D. B., Peres, K. C., Ribeiro, R. P., Colle, D., dos Santos, A. A., Moreira, E. L. G., Souza, D. O., Figueiredo, C. P., & Farina, M. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.11.036 · Cited by 85 · see citing works
Jones, P. B., Adams, K. W., Rozkalne, A., Spires-Jones, T. L., Hshieh, T. T., Hashimoto, T., von Armin, C. A. F., Mielke, M., Bacskai, B. J., & Hyman, B. T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014586 · Cited by 84 · see citing works
Self-citationVitek, M. P., Christensen, D. J., Wilcock, D. M., Davis, J., Nostrand, W. E. V., Li, F. Q., & Colton, C. A. (2012) · Neurodegenerative Diseases · doi:10.1159/000334914 · Cited by 82 · see citing works
Ghosal, K., Haag, M., Verghese, P. B., West, T., Veenstra, T., Braunstein, J. B., Bateman, R. J., Holtzman, D. M., & Landreth, G. E. (2016) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.06.001 · Cited by 73 · see citing works
Aβ immunotherapy for Alzheimer’s disease: effects on apoE and cerebral vasculopathy
Sakai, K., Boche, D., Carare, R., Johnston, D., Holmes, C., Love, S., & Nicoll, J. A. R. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1340-9 · Cited by 72 · see citing works
Ramanan, V. K., Castillo, A. M., Knopman, D. S., Graff‐Radford, J., Lowe, V. J., Petersen, R. C., Jack, C. R., Mielke, M. M., & Vemuri, P. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.13909 · Cited by 71 · see citing works
Role of Apolipoprotein E in β-Amyloidogenesis
Hori, Y., Hashimoto, T., Nomoto, H., Hyman, B. T., & Iwatsubo, T. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.622209 · Cited by 66 · see citing works
Self-citationChampagne, D. L., Pearson, D., Dea, D., Rochford, J. M., & Poirier, J. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00361-0 · Cited by 66 · see citing works
Pankiewicz, J. E., Guridi, M., Kim, J., Asuni, A. A., Sanchez, S., Sullivan, P. M., Holtzman, D. M., & Sadowski, M. J. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0075-0 · Cited by 57 · see citing works
Ghosal, K., Stathopoulos, A. M., Thomas, D. G., Phenis, D., Vitek, M. P., & Pimplikar, S. W. (2012) · Neurodegenerative Diseases · doi:10.1159/000341299 · Cited by 50 · see citing works
Haplotype analysis of APOE intragenic SNPs
Babenko, V. N., Afonnikov, D. A., Ignatieva, E. V., Klimov, A. V., Gusev, F. E., & Rogaev, E. I. (2018) · BMC Neuroscience · doi:10.1186/s12868-018-0413-4 · Cited by 47 · see citing works
Analysis of Whole-Exome Sequencing Data for Alzheimer Disease Stratified by APOE Genotype
Ma, Y., Jun, G., Zhang, X., Chung, J., Naj, A. C., Chen, Y., Bellenguez, C., Hamilton‐Nelson, K. L., Martin, E. R., Kunkle, B. W., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1456 · Cited by 47 · see citing works
Koriath, C., Lashley, T., Taylor, W., Druyeh, R., Dimitriadis, A., Denning, N., Williams, J. H., Warren, J. D., Fox, N. C., Schott, J. M., et al. (2019) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.01.010 · Cited by 44 · see citing works
Pocovi, M., Cenarro, A., Civeir, F., Myers, R. H., Casao, E., Esteban, M., & Ordovas, J. M. (1996) · Atherosclerosis · doi:10.1016/0021-9150(95)06745-0 · Cited by 42 · see citing works
ApoE mimetic improves pathology and memory in a model of Alzheimer’s disease
Krishnamurthy, K., Cantillana, V., Wang, H., Sullivan, P. M., Kolls, B. J., Ge, X., Lin, Y., Mace, B., & Laskowitz, D. T. (2020) · Brain Research · doi:10.1016/j.brainres.2020.146685 · Cited by 39 · see citing works
Muñoz-Cabrera, J. M., Sandoval-Hernández, A. G., Niño, A., Báez, T., Bustos-Rangel, A., Cardona‐Gómez, G. P., Múnera, A., & Arboleda, G. (2019) · PLoS ONE · doi:10.1371/journal.pone.0223578 · Cited by 38 · see citing works
Genetic resilience to Alzheimer's disease in <i>APOE</i> ε4 homozygotes: A systematic review
Huq, A. J., Fransquet, P., Laws, S. M., Ryan, J., Sebra, R., Masters, C. L., Winship, I. M., James, P. A., & Lacaze, P. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.05.011 · Cited by 35 · see citing works
Pankiewicz, J. E., Baquero-Buitrago, J., Sanchez, S., Lopez-Contreras, J., Kim, J., Sullivan, P. M., Holtzman, D. M., & Sadowski, M. J. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0156-1 · Cited by 34 · see citing works
Assessment of APOE in atypical parkinsonism syndromes
Sabir, M. S., Blauwendraat, C., Ahmed, S., Serrano, G. E., Beach, T. G., Perkins, M., Rice, A. C., Masliah, E., Morris, C. M., Pihlstrom, L., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.02.016 · Cited by 28 · see citing works
Kara, E., Marks, J. D., Fan, Z., Klickstein, J. A., Roe, A. D., Krogh, K. A., Wegmann, S., Maesako, M., Luo, C. C., Mylvaganam, R., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.784264 · Cited by 23 · see citing works
Self-citationKara, E., Marks, J. D., Roe, A. D., Commins, C., Fan, Z., Calvo-Rodriguez, M., Wegmann, S., Hudry, E., & Hyman, B. T. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.001388 · Cited by 20 · see citing works
Self-citationProkopenko, I., Miyakawa, G., Zheng, B., Heikkinen, J., Petrova, D., Udeh‐Momoh, C. T., Claringbould, A., Neumann, J., Haytural, H., Kaakinen, M., et al. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.08.005 · Cited by 20 · see citing works
Mezlini, A. M., Magdamo, C., Merrill, E., Chibnik, L. B., Blacker, D., Hyman, B. T., & Das, S. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200228 · Cited by 7 · see citing works
Self-citationDiagnostic criteria for primary progressive mutiple sclerosis: a position paper.
(2000) · Pure Amsterdam UMC · doi:10.1002/1531-8249(200006)47:6 · Cited by 2 · see citing works
Flagged first, then by citations
Research works printed but not linked: 3
- [9]Tang MX, Stern Y, Marder K, The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA 1998; 279: 751– 5. 9508150
- [15]Serrano-Pozo A, Qian J, Monsell SE, Betensky RA, Hyman BT. APOEε2 is associated with milder clinical and pathological Alzheimer disease. Ann Neurol 2015; 77: 917– 29. 25623662 PMC4447539
- [40]Holtzman DM, Fagan AM, Mackey B, Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer’s disease model. Ann Neurol 2000; 47: 739– 47. 10852539
Cited by
Sorted by citations
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138 · see citing works
“123 ,181 – 184 Consequently, diminishing APOE4 expression in A β plaque-associated microglia may offer an effective approach.”
BackgroundMicroglia polarization from M1 to M2 in neurodegenerative diseases
Guo, S., Wang, H., & Yin, Y. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.815347 · Cited by 920 · see citing works
Oxidative stress: The core pathogenesis and mechanism of Alzheimer’s disease
Bai, R., Guo, J., Ye, X.-Y., Xie, Y., & Xie, T. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101619 · Cited by 813 · see citing works
Huang, J., Sun, W., Wang, Z., Lv, C., Zhang, T., Zhang, D., Dong, W., Shao, L., He, L., Ji, X., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02254-z · Cited by 198 · see citing works
Periodontal microorganisms and Alzheimer disease – A causative relationship?
Jungbauer, G., Stähli, A., Zhu, X., Auber Alberi, L., Sculean, A., & Eick, S. (2022) · Periodontology 2000 · doi:10.1111/prd.12429 · Cited by 174 · see citing works
Clonal hematopoiesis is associated with protection from Alzheimer’s disease
Bouzid, H., Belk, J. A., Jan, M., Qi, Y., Sarnowski, C., Wirth, S., Ma, L., Chrostek, M. R., Ahmad, H., Nachun, D., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02397-2 · Cited by 169 · see citing works
Pires, M., & Rego, A. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24010778 · Cited by 157 · see citing works
Astrocyte transcriptomic changes along the spatiotemporal progression of Alzheimer’s disease
Serrano-Pozo, A., Li, H., Li, Z., Muñoz-Castro, C., Jaisa-aad, M., Healey, M. A., Welikovitch, L. A., Jayakumar, R., Bryant, A. G., Noori, A., et al. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01791-4 · Cited by 140 · see citing works
Self-citationKaji, S., Berghoff, S. A., Spieth, L., Schlaphoff, L., Sasmita, A. O., Vitale, S., Büschgens, L., Kedia, S., Zirngibl, M., Nazarenko, T., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.09.014 · Cited by 104 · see citing works
Ren, F., Wei, J., Chen, Q., Hu, M., Yu, L., Mi, J., Zhou, X., Qin, D., Wu, J., & Wu, A. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.07.030 · Cited by 97 · see citing works
Jackson, R. J., Keiser, M. S., Meltzer, J. C., Fykstra, D. P., Dierksmeier, S. E., Hajizadeh, S., Kreuzer, J., Morris, R., Melloni, A., Nakajima, T., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.03.024 · Cited by 86 · see citing works
Self-citationArtificial intelligence for drug discovery and development in Alzheimer's disease
Qiu, Y., & Cheng, F. (2024) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2024.102776 · Cited by 83 · see citing works
Anti-inflammatory role of gold nanoparticles in the prevention and treatment of Alzheimer's disease
Aili, M., Zhou, K., Zhan, J., Zheng, H., & Luo, F. (2023) · Journal of Materials Chemistry B · doi:10.1039/d3tb01023f · Cited by 80 · see citing works
Targeting autophagy in Alzheimer’s disease: Animal models and mechanisms
Zhang, X.-W., 澳门大学中华医药研究院中药质量研究国家重点实验室, 澳. 凼. 9., State Key Laboratory of Quality Research in Chinese Medicine, I. O. C. M. S., Zhu, X.-X., Tang, D.-S., Lu, J.-H., 佛山大学广东省动物分子设计与精准育种重点实验室, 广., & Guangdong Provincial Key Laboratory of Animal Molecular Design and Precise Breeding, G. E. T. C. O. G. P. (2023) · Zoological Research · doi:10.24272/j.issn.2095-8137.2023.294 · Cited by 77 · see citing works
Haddad, M., Hervé, V., Ben Khedher, M. R., Rabanel, J.-M., & Ramassamy, C. (2021) · Antioxidants & Redox Signaling · doi:10.1089/ars.2020.8129 · Cited by 68 · see citing works
Yang, J., Zhi, W., & Wang, L. (2024) · Molecules · doi:10.3390/molecules29122812 · Cited by 63 · see citing works
“Apolipoprotein E (ApoE) also plays a key role in the microglia-dependent and astrocyte-dependent regulation of tau pathology and tau-induced neurodegeneration [41,42].”
BackgroundApolipoproteins: New players in cancers
He, Y., Chen, J., Ma, Y., & Chen, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1051280 · Cited by 52 · see citing works
sc2GWAS: a comprehensive platform linking single cell and GWAS traits of human
Yin, M., Feng, C., Yu, Z., Zhang, Y., Li, Y., Wang, X., Song, C., Guo, M., & Li, C. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkae1008 · Cited by 51 · see citing works
Chatterjee, M., Özdemir, S., Kunadt, M., Koel‐Simmelink, M., Boiten, W., Piepkorn, L., Pham, T. V., Chiasserini, D., Piersma, S. R., Knol, J. C., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13066 · Cited by 47 · see citing works
Wang, Y.-Y., Ge, Y.-J., Tan, C.-C., Cao, X.-P., Tan, L., & Xu, W. (2021) · Journal of Alzheimer's Disease · doi:10.3233/jad-201606 · Cited by 49 · see citing works
Cholesterol Dysmetabolism in Alzheimer’s Disease: A Starring Role for Astrocytes?
Staurenghi, E., Giannelli, S., Testa, G., Sottero, B., Leonarduzzi, G., & Gamba, P. (2021) · Antioxidants · doi:10.3390/antiox10121890 · Cited by 44 · see citing works
Polis, B., & Samson, A. O. (2024) · Journal of Alzheimer's Disease · doi:10.3233/jad-240058 · Cited by 43 · see citing works
Sun, G. G., Wang, C., Mazzarino, R. C., Perez-Corredor, P. A., Davtyan, H., Blurton-Jones, M., Lopera, F., Arboleda-Velasquez, J. F., & Shi, Y. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114982 · Cited by 36 · see citing works
Tripathy, R. K., Frohock, Z., Wang, H., Cary, G. A., Keegan, S., Carter, G. W., & Li, Y. (2025) · npj Systems Biology and Applications · doi:10.1038/s41540-025-00519-9 · Cited by 36 · see citing works
Protective mechanisms against Alzheimer's disease in APOE3‐Christchurch homozygous astrocytes
Tian, X., Rivera, E. K., Hwang, I., Nikitina, A. A., Smith, J. A., Cho, Y. J., Sala‐Jarque, J., DuBose, A., Andriola, C., Gollan‐Myers, T., et al. (2025) · Alzheimer's & Dementia · doi:10.1002/alz.70589 · Cited by 7 · see citing works
Wei, Z., Pan, X., Cui, X., Zhang, J., Dai, X., Zeng, Y., & Chen, X. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1537388 · Cited by 7 · see citing works
Al‐Amin, M. M., Kim, B., Karahan, H., Tate, M. D., Walsh, S. P., Puntambekar, S. S., Bissel, S. J., Lamb, B. T., Wang, N., & Kim, J. (2025) · Alzheimer's & Dementia · doi:10.1002/alz.70791 · Cited by 6 · see citing works
Karahan, H., Hartigan, K., Al‐Amin, M. M., John, S. K., McCord, B., Wijeratne, H. R. S., Acri, D. J., Smith, D. C., Dabin, L. C., Cordero, H. M. R., et al. (2025) · Alzheimer's & Dementia · doi:10.1002/alz.70949 · Cited by 2 · see citing works
Singh, T., Bridgeman, E., Baker, A. J., Noblet, H. A., Yang, K. Y., Kang, S., Lim, K. H., Lee, S. S., Amundsen, N. M., Lee, Y., et al. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.107246 · Cited by 1 · see citing works
Kopp, K., Silva, P., Damm, F., & Cosma, N. C. (2026) · Biomedicines · doi:10.3390/biomedicines14051012
- Authors
- Serrano-Pozo, A., Das, S., & Hyman, B. T.
- Affiliations
- Harvard University (US)
- Corresponding author
- Hyman, Bradley T
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 20
- Issue
- 1
- Pages
- 68-80
- ISSN
- 1474-4422 (ISSN-L)
- PMC
- PMC8096522
- OpenAlex
- W3111203418
- Cited by
- 1,037
- References
- 108
- Citations by year
- 2026: 199 · 2025: 264 · 2024: 190 · 2023: 179 · 2022: 139 · 2021: 65 · 2012: 1
- FWCI
- 12.25
- Type
- journal article
- Language
- en
- Update notices
- erratum (2021-02-01)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nc-nd)
- Funders
- National Institute of Neurological Disorders and Stroke (U01NS111671\u201301)
- National Institute on Aging (K08AG064039, 1R01AG047644\u201301)
- Alzheimer's Association (AACF-17\u2013524184)
- Massachusetts General Hospital
- U.S. Department of Justice
- Novartis
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- apolipoprotein E, Alzheimer's disease, APOE ε4, APOE ε2, genetic risk factors, amyloid-beta, microglia, astrocytes, blood-brain barrier disruption, mouse model
- MeSH terms
- Alzheimer Disease, Animals, Apolipoproteins E, Humans, Genetic Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
